[New therapeutic options for mesothelioma].
Ruffié
P
P
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004317:Doxorubicin / Q000008:administration & dosage; D005493:Folic Acid Antagonists / Q000008:administration & dosage; D005602:France / Q000453:epidemiology; D006801:Humans; D008654:Mesothelioma / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D016685:Mitomycin / Q000008:administration & dosage; D009367:Neoplasm Staging; D018579:Patient Selection; D011013:Pneumonectomy; D011379:Prognosis; D011799:Quinazolines / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors; D016019:Survival Analysis; D013876:Thiophenes / Q000008:administration & dosage; D016896:Treatment Outcome; D014751:Vindesine / Q000008:administration & dosage; D000093542:Gemcitabine
D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D005493:Folic Acid Antagonists; D011799:Quinazolines; D013876:Thiophenes; D003841:Deoxycytidine; D016685:Mitomycin; D004317:Doxorubicin; C068874:raltitrexed; D002945:Cisplatin; D014751:Vindesine; D000093542:Gemcitabine